Literature DB >> 33798472

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver.

Alice Bertocchi1, Sara Carloni2, Paola Simona Ravenda3, Giovanni Bertalot3, Ilaria Spadoni2, Antonino Lo Cascio2, Sara Gandini3, Michela Lizier1, Daniele Braga1, Francesco Asnicar4, Nicola Segata4, Chris Klaver3, Paola Brescia1, Elio Rossi5, Achille Anselmo1, Silvia Guglietta3, Annalisa Maroli1, Paola Spaggiari1, Noelia Tarazona6, Andres Cervantes6, Silvia Marsoni7, Luca Lazzari7, Maria Giovanna Jodice3, Chiara Luise3, Marco Erreni1, Salvatore Pece8, Pier Paolo Di Fiore8, Giuseppe Viale8, Antonino Spinelli2, Chiara Pozzi1, Giuseppe Penna1, Maria Rescigno9.   

Abstract

Metastasis is facilitated by the formation of a "premetastatic niche," which is fostered by primary tumor-derived factors. Colorectal cancer (CRC) metastasizes mainly to the liver. We show that the premetastatic niche in the liver is induced by bacteria dissemination from primary CRC. We report that tumor-resident bacteria Escherichia coli disrupt the gut vascular barrier (GVB), an anatomical structure controlling bacterial dissemination along the gut-liver axis, depending on the virulence regulator VirF. Upon GVB impairment, bacteria disseminate to the liver, boost the formation of a premetastatic niche, and favor the recruitment of metastatic cells. In training and validation cohorts of CRC patients, we find that the increased levels of PV-1, a marker of impaired GVB, is associated with liver bacteria dissemination and metachronous distant metastases. Thus, PV-1 is a prognostic marker for CRC distant recurrence and vascular impairment, leading to liver metastases.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Escherichia coli; bacteria; colorectal cancer; gut vascular barrier; inflammatory monocytes; macrophages; metastases; neutrophils; premetastatic niche; vasculature

Mesh:

Year:  2021        PMID: 33798472     DOI: 10.1016/j.ccell.2021.03.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   38.585


  36 in total

1.  Bacteria prepare the niche.

Authors:  Ulrike Harjes
Journal:  Nat Rev Cancer       Date:  2021-06       Impact factor: 60.716

Review 2.  Redrawing therapeutic boundaries: microbiota and cancer.

Authors:  Jonathan Sholl; Gregory D Sepich-Poore; Rob Knight; Thomas Pradeu
Journal:  Trends Cancer       Date:  2021-11-26

Review 3.  The Cancer Microbiome: Recent Highlights and Knowledge Gaps.

Authors:  Reece J Knippel; Julia L Drewes; Cynthia L Sears
Journal:  Cancer Discov       Date:  2021-08-16       Impact factor: 39.397

4.  Microbiome in drug resistance to colon cancer.

Authors:  Kavita Pandey; Shahid Umar
Journal:  Curr Opin Physiol       Date:  2021-08-17

5.  [Centromere protein U is highly expressed in colorectal cancer and associated with a poor long-term prognosis].

Authors:  X Zhang; Z Yang; Q Hu; L Zuo; X Song; Z Geng; J Li; Y Wang; S Ge; J Hu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-08-20

Review 6.  Gut microbiome in gastrointestinal cancer: a friend or foe?

Authors:  Yang Liu; Yoshifumi Baba; Takatsugu Ishimoto; Xi Gu; Jun Zhang; Daichi Nomoto; Kazuo Okadome; Hideo Baba; Peng Qiu
Journal:  Int J Biol Sci       Date:  2022-06-21       Impact factor: 10.750

7.  Bacteria break barrier to promote metastasis.

Authors:  Yoshitaka Murota; Christian Jobin
Journal:  Cancer Cell       Date:  2021-04-22       Impact factor: 31.743

Review 8.  The gut microbiota can be a potential regulator and treatment target of bone metastasis.

Authors:  Kelly F Contino; Hariom Yadav; Yusuke Shiozawa
Journal:  Biochem Pharmacol       Date:  2022-01-15       Impact factor: 5.858

9.  In the literature: June 2021.

Authors:  V Gambardella; L Candia; M Tapia; J M Cejalvo; A Cervantes
Journal:  ESMO Open       Date:  2021-06-04

Review 10.  Intestinal Models for Personalized Medicine: from Conventional Models to Microfluidic Primary Intestine-on-a-chip.

Authors:  Xiang-Guang Li; Ming-Xia Chen; Su-Qing Zhao; Xiu-Qi Wang
Journal:  Stem Cell Rev Rep       Date:  2021-06-28       Impact factor: 6.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.